Table 2.

Summary of causes of discontinuation of ibrutinib with rituximab (IR) with patient characteristics (n = 21)

Patient characteristics
Age (y)GenderFISH#IGHV mutation statusCause of discontinuationType of complicationDuration of ibrutinib (months)Salvage treatmentSurvival statusOn study death (Y/N)Post-IR survival (months)Causes of deathDisease transformation (Y/N)
65MaleNeg.UMStem cell transplantNone12.6UnknownDeadN4.5Disease progressionNo
63Female17pUMStem cell transplantNone14.9NoneAliveN23.4No
62Male17pUMComplicationsEar infections16.8DeadY0.0Pulmonary complicationsNo
67Male11qUMComplicationsUnknown, found dead in his sleep16.4DeadY0.0UnknownNo
61Male17pUMComplicationsPulmonary infections9.5DeadY1.5Pulmonary infectionsNo
68Male11qUMComplicationsDiarrhea, subdural hematoma21.5Restarted ibrutinibAliveN14.8No
72Male11qUMComplicationsProgressive lung cancer31.8On ibrutinibDeadY0.0Lung cancerNo
76Male17pUMComplicationsMultifocal aspergillosis2.1DeadY0.2Pneumonia, brain abscessNo
57Female17pMComplicationsMucositis6.0OFAR, ibrutinib restartedDeadN18.5SepsisNo
82Male17pUMComplicationsComp-CHF, COPD8.4DeadN3.9CHF, COPDNo
61Female17pUMComplicationsToxicity-arthritis45PlanningAliveN0No
73Female17pUMDisease progression14.4RituximabDiedN1.4Resistant diseaseNo
58Male17pUMDisease progression34.3Idelalisib + rituximabAliveN4.2No
52Male13qUMDisease progression21.4ABT-199, HCVAD, idelalisibDiedN15.8Resistant disease with TP53 acquisitionNo
35Female11qUMDisease progression6.8DiedN2.1PneumoniaNo
76Female17pUMDisease progression45.1Ibrutinib with BRAliveN0.0No
65Female17pUMDisease progression13.1R-MP then IPI-145DiedN2.5Progressive diseaseYes
73Female17pUMDisease progression32.3Expt. agentsDiedN8.6InfectionsNo
73Female17pUMDisease progression21.9ABT-199DiedN3.1Progressive diseaseYes
78Female17pUMDisease progression22.5OfatumumabAliveN20.0No
65Male17pNDDisease progression47.1VenetoclaxAliveN2.9No
  • Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HCVAD, hyper-CVAD (cyclophosphamide, vincristine, adriamycin, and dexamethasone); M, mutated; ND, not detected; OFAR, oxaliplatin, fludarabine, cytarabine, and rituximab; UM, unmutated.